Trial Profile
A Phase II Study of Merestinib in Non-Small Cell Lung Cancers Harboring MET Exon 14 Mutations and Solid Tumors With NTRK Rearrangements
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Apr 2023
Price :
$35
*
At a glance
- Drugs Merestinib (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Therapeutic Use
- 02 Jan 2020 Status changed from recruiting to active, no longer recruiting.
- 15 Nov 2016 Status changed from not yet recruiting to recruiting.
- 03 Oct 2016 New trial record